Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS XR ODT versus METHYLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS XR ODT versus METHYLIN.
ADZENYS XR-ODT vs METHYLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adzenys XR-ODT contains amphetamine, a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Methylphenidate is a central nervous system stimulant. It blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Initial: 9.4 mg orally once daily in the morning; titrate in increments of 9.4 mg per week based on tolerability and response. Maximum: 56.4 mg once daily.
10 mg orally twice daily, administered 4-6 hours apart; doses may be adjusted in 5-10 mg increments weekly up to 60 mg/day.
None Documented
None Documented
Approximately 9-14 hours in adults, 8-11 hours in children (6-12 years). Extended-release pharmacokinetics produce a longer clinical duration compared to immediate-release formulations.
2-4 hours (short elimination half-life, requiring multiple daily dosing; immediate-release: 3-4 hours, extended-release: 3-6 hours)
Renal: approximately 90% as unchanged drug and metabolites (30%-40% as amphetamine, 40%-50% as hippuric acid and benzoic acid). Fecal: <4%. Biliary: negligible.
Renal: 90% (mainly as metabolites, 30-50% as unchanged drug); fecal: <1%
Category C
Category C
CNS Stimulant
CNS Stimulant